Plain-English translation of NCT06652243 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called cell injection, which uses specially engineered immune cells designed to find and attack liver cancer cells. The study is designed for people with advanced liver cancer that hasn't responded to standard treatments like checkpoint inhibitors or targeted therapies. Researchers want to learn whether this medication is safe and whether it can help control the cancer.
Many people with advanced liver cancer stop responding to standard treatments, leaving few options available. This trial exists to explore whether this new immune cell approach can offer hope to patients who have exhausted other treatment choices.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive injections of the new immune cells on a 28-day cycle — specifically on days 0, 7, and 14 of each cycle. The study uses a stepwise approach, starting with lower doses and increasing to higher doses as safety is confirmed. You would need to attend regular visits for blood tests, imaging scans, and physical exams to monitor how you respond to treatment and track any side effects. The entire study involves about 12 patients total, and you would be closely followed to help doctors understand whether this treatment is safe and effective.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators
Celest Therapeutics (Shanghai) Co., Ltd., Senti Biosciences
Enrollment target
~12 participants
Started
November 2024
Primary completion
October 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qi Li, MD
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.